aprindine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 231 | 37640-71-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 8.86 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 85 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1996 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BB04 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ib |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ventricular arrhythmia | indication | 44103008 | |
| Supraventricular arrhythmia | indication | 72654001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.56 | Basic |
| pKa2 | 6.73 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Calmodulin | Cytosolic other | INHIBITOR | ID50 | 4.75 | WOMBAT-PK | SCIENTIFIC LITERATURE | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | WOMBAT-PK | |||||||
| Cytochrome P450 2D6 | Enzyme | Ki | 7.76 | WOMBAT-PK | |||||
| Sodium channel protein type 5 subunit alpha | Ion channel | WOMBAT-PK | |||||||
| Sodium/calcium exchanger 1 | Transporter | IC50 | 4.30 | WOMBAT-PK | |||||
| Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | IC50 | 4.36 | WOMBAT-PK | |||||
| Proteasome subunit alpha type-1 | Enzyme | IC50 | 5.40 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| N0000167348 | NUI |
| D01326 | KEGG_DRUG |
| 1054 | RXNORM |
| C0003639 | UMLSCUI |
| CHEBI:135370 | CHEBI |
| CHEMBL1213033 | ChEMBL_ID |
| DB01429 | DRUGBANK_ID |
| D001073 | MESH_DESCRIPTOR_UI |
| 2218 | PUBCHEM_CID |
| 3179 | INN_ID |
| 33237-74-0 | SECONDARY_CAS_RN |
| 5Y48085P9Q | UNII |
| CHEMBL2104501 | ChEMBL_ID |
| 005233 | NDDF |
| 005247 | NDDF |
Pharmaceutical products:
None